
A


Percent Seizure
120
100
80
60
40
20
0
89 ng/mL
(283 nM)
344 ng/mL
(1.09 uM)
878 ng/mL
(2.79 uM)
*
Saline
MPEP 30mg/kg
30% Captisol
3
10
30
Allopregnanolone

B




Percent Survival
120
100
80
60
40
20
0
*
Saline
MPEP 30mg/kg
30% Captisol
3
10
30
Allopregnanolone

FIG. 1

A


15% HPβCD (i.p.) - PTZ (85 mg/kg, i.p.)
Valproate (400 mg/kg, i.p.) - PTZ (85 mg/kg, i.p.)
SGE-102 (3 mg/kg, i.p.) - PTZ (85 mg/kg, i.p.) - 88.2 ng/mL
SGE-102 (10 mg/kg, i.p.) - PTZ (85 mg/kg, i.p.) - 321 ng/mL
SGE-102 (30 mg/kg, i.p.) - PTZ (85 mg/kg, i.p.) - 673 ng/mL
Seizure Rank (0-6)
0
2
4
6
8
10
10
20
30
Time (min)

B



15% HPβCD (i.p.) - PTZ (85 mg/kg, i.p.)
Valporate (400 mg/kg, i.p.) - PTZ (85 mg/kg, i.p.)
SGE-102 (3 mg/kg, i.p.) - PTZ (85 mg/kg, i.p.)
SGE-102 (10 mg/kg, i.p.) - PTZ (85 mg/kg, i.p.)
SGE-102 (30 mg/kg, i.p.) - PTZ (85 mg/kg, i.p.)
Latency to death (sec)
0
500
1000
1500
2000
2500
3000

FIG. 2



Plasma Exposure of ALLO from Human SE Study (LLOQ 16nM)
PLASMA (nM)
160
140
120
100
80
60
40
20
0
-2 9 19 29 39 49 59 69 79 89 99 109 119 129 139
HOURS
Dosing Schedule
ALLO 1.5 mg/mL (1-120 hrs)

FIG. 3





Table 1.

| Time point (hr) | % Difference Plasma IM relative to IV |
|---|---|
| 0.5 | 838.26% |
| 1 | 916.52% |
| 2 | 671.92% |

FIG. 4A

**Mean brain concentration-time profiles of Allopregnanolone after single IM or IV dose in 30% Captisol. SD Rats (N=2/time point)**





Table 2.

| Time point (hr) | % Difference Brain IM relative to IV |
|---|---|
| 1 | 506.17% |

FIG. 4B



SAGE (Captisol) Formulation; IV Chronic x 5d
LATENCY TO FALL (sec)
70
60
50
40
30
20
10
0
SHAM (10)
PBBI_VEH (10)
LOW PROG (8)
HIGH PROG (12)
10 rpm
15 rpm
20 rpm
PRE-PBBI
DAY 6
DAY 9

FIG. 5A



MEAN MOTOR SCORE
MEAN MOTOR/BALANCE SCORE
45
40
35
30
25
20
15
10
5
0
p < .06 vs. PBBI
PBBI
2.5/1.25
5.0/2.50
SAGE (mg/kg/hx5d)

FIG. 5B